AEM vs IDR

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

IDR presents a dichotomy between exceptional operational growth and severe valuation misalignment. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts explosive revenue and earnings growth, the stock is trading at a massive premium to its Graham Number ($13.29) and Intrinsic Value ($33.63). This valuation gap, combined with aggressive insider selling by the CEO and CFO and a bearish technical trend, suggests the current price is driven by speculation rather than fundamental value.